ArticleAnnals of hematology2025
Assessment of ferritin and hepcidin levels in splenectomised and non-splenectomised β-thalassemia major patients and exploring a potential correlation with von Willebrand factor and ADAMTS-13.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iron overload is a major complication in β-thalassemia major (β-TM) patients, resulting from ineffective erythropoiesis, increased gastrointestinal iron absorption and multiple blood transfusions. Excess iron accumulates in various organs, leading to organ dysfunction, and increased risk of thrombotic events. In this study we aim to determine levels of ferritin and its regulation hormone hepcidin in multi-transfused splenectomised and non-splenectomised β-thalassemia major patients and assess a possible correlation with the coagulation protein von Willebrand factor (vWF) and its cleaving protease ADAMTS-13. The study was conducted on 80 β-thalassemia major patients and 80 age- and sex-matched healthy controls. Plasma levels of vWF, ADAMTS-13, and hepcidin were assessed using the ELISA method. All patients presented with significantly higher levels of ferritin compared to normal controls (p < 0.001), while hepcidin levels were barely higher in patients (p = 0.05). Ferritin had a positive correlation with vWF antigen levels (r = 0.222, p = 0.05), ADAMTS-13 antigen levels (r = 0.334, p = 0.002) and ADAMTS-13 activity levels (r = 0.353, p = 0.001) in patients. Splenectomised patients had significantly higher levels of white blood cell counts, platelet counts and vWF antigen levels compared to non-splenectomised patients (p < 0.05), but ferritin and hepcidin levels were comparable between the two groups (p > 0.05). Hepcidin was not found to be correlated with any of the measured parameters in patients (p > 0.05). Iron overload is well manifested in our study group despite continuous chelation therapy. Unlike hepcidin, ferritin appeared to be associated with increased secretion of vWF and ADAMTS-13 in patients, while splenectomy had no effect on ferritin or hepcidin levels. These findings highlight the importance of proper iron monitoring in β-TM and recognition of thrombotic risks in managing this anemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.